迈威生物：发行境外上市外资股（H股）获得中国证监会备案

Core Viewpoint - The company, Maiwei Biotechnology, has received a notification from the China Securities Regulatory Commission regarding its plan for overseas issuance and listing in Hong Kong [1] Group 1: Company Actions - The company plans to issue no more than 62,664,600 overseas listed ordinary shares [1] - The company is required to report any significant events to the China Securities Regulatory Commission through the designated management information system until the completion of the overseas issuance and listing [1] - Within 15 working days after the completion of the overseas issuance and listing, the company must report the issuance and listing status to the China Securities Regulatory Commission [1] Group 2: Regulatory Compliance - The company must strictly adhere to relevant domestic and foreign laws, regulations, and rules during the overseas issuance and listing process [1]